TARS
Price:
$54.1
Market Cap:
$2.07B
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceutical...[Read more]
Industry
Biotechnology
IPO Date
2020-10-16
Stock Exchange
NASDAQ
Ticker
TARS
According to Tarsus Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 1.96B. This represents a change of 113.87% compared to the average of 918.43M of the last 4 quarters.
The mean historical Enterprise Value of Tarsus Pharmaceuticals, Inc. over the last ten years is 351.07M. The current 1.96B Enterprise Value has changed 55.85% with respect to the historical average. Over the past ten years (40 quarters), TARS's Enterprise Value was at its highest in in the September 2024 quarter at 1.16B. The Enterprise Value was at its lowest in in the March 2018 quarter at 0.
Average
351.07M
Median
326.56M
Minimum
85.84M
Maximum
672.66M
Discovering the peaks and valleys of Tarsus Pharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 300.42%
Maximum Annual Enterprise Value = 672.66M
Minimum Annual Increase = -56.44%
Minimum Annual Enterprise Value = 85.84M
Year | Enterprise Value | Change |
---|---|---|
2023 | 401.80M | 29.85% |
2022 | 309.42M | 5.59% |
2021 | 293.03M | -56.44% |
2020 | 672.66M | 95.71% |
2019 | 343.71M | 300.42% |
The current Enterprise Value of Tarsus Pharmaceuticals, Inc. (TARS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
334.75M
5-year avg
404.12M
10-year avg
351.07M
Tarsus Pharmaceuticals, Inc.’s Enterprise Value is greater than LianBio (-66141903.00), greater than Aldeyra Therapeutics, Inc. (272.74M), greater than Travere Therapeutics, Inc. (1.85B), greater than Eton Pharmaceuticals, Inc. (312.00M), greater than Connect Biopharma Holdings Limited (-53600395.00), greater than Acumen Pharmaceuticals, Inc. (104.95M), greater than Nuvation Bio Inc. (889.89M), greater than Eledon Pharmaceuticals, Inc. (247.04M), greater than Opthea Limited (551.85M), greater than Centessa Pharmaceuticals plc (1.86B), less than Nuvalent, Inc. (5.51B), greater than Genfit S.A. (179.69M), greater than Monte Rosa Therapeutics, Inc. (350.02M), greater than Design Therapeutics, Inc. (326.08M), greater than Werewolf Therapeutics, Inc. (-17871760.00), greater than Ikena Oncology, Inc. (39.93M), greater than Stoke Therapeutics, Inc. (447.90M), greater than PepGen Inc. (106.16M), greater than Tyra Biosciences, Inc. (652.68M), greater than Entrada Therapeutics, Inc. (642.23M), greater than Pharvaris N.V. (675.52M), greater than Rallybio Corporation (10.42M),
Company | Enterprise Value | Market cap |
---|---|---|
-66141903.00 | $34.47M | |
272.74M | $285.25M | |
1.85B | $1.48B | |
312.00M | $332.14M | |
-53600395.00 | $56.25M | |
104.95M | $108.14M | |
889.89M | $908.73M | |
247.04M | $253.29M | |
551.85M | $4.46B | |
1.86B | $2.17B | |
5.51B | $5.88B | |
179.69M | $182.76M | |
350.02M | $431.90M | |
326.08M | $353.88M | |
-17871760.00 | $68.18M | |
39.93M | $76.73M | |
447.90M | $595.61M | |
106.16M | $129.41M | |
652.68M | $750.25M | |
642.23M | $658.97M | |
675.52M | $1.02B | |
10.42M | $35.51M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Tarsus Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Tarsus Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Tarsus Pharmaceuticals, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Tarsus Pharmaceuticals, Inc. (TARS)?
What is the 3-year average Enterprise Value for Tarsus Pharmaceuticals, Inc. (TARS)?
What is the 5-year average Enterprise Value for Tarsus Pharmaceuticals, Inc. (TARS)?
How does the current Enterprise Value for Tarsus Pharmaceuticals, Inc. (TARS) compare to its historical average?